$-0.02
(Market cap
$10 Mln
Recently Viewed
Clear AllMarket cap
$10 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
8.9
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-29 Mln
ROE
-5.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.6
Debt to Equity
-4.4
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
11,711,600
CFO
$-151.64 Mln
EBITDA
$-165.06 Mln
Net Profit
$-173.03 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
IMV Inc (IMV)
| -96.7 | -19.3 | -85.0 | -98.9 | -85.7 | -72.3 | -- |
|
BSE Sensex*
| -9.0 | 5.0 | -8.1 | -4.3 | 7.6 | 9.8 | 11.9 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
IMV Inc (IMV)
| -80.1 | -60.4 | 6.2 | -43.9 | -13.5 | 273.8 | -1.3 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
IMV Inc (IMV)
|
0.1 | 9.8 | 0.0 | -38.5 | -- | -515.3 | -- | 8.9 |
| 4.0 | 30.3 | 0.2 | -38.5 | -17,358.1 | -138.3 | -- | 1.0 |
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate... includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada. Read more
CEO & Director
Mr. Andrew Hall M.Sc.
CEO & Director
Mr. Andrew Hall M.Sc.
Headquarters
Dartmouth, NS
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of IMV Inc (IMV) is $0.08 (NASDAQ) as of 26-Jun-2023 09:30 EDT. IMV Inc (IMV) has given a return of -85.71% in the last 3 years.
Since, TTM earnings of IMV Inc (IMV) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of IMV Inc (IMV) are Rs -- and Rs -- as of 05-May-2026.
IMV Inc (IMV) has a market capitalisation of $ 10 Mln as on 28-Jun-2023. As per SEBI classification, it is a company.
Before investing in IMV Inc (IMV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.